Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA May Allow "Qualitative" Labels For Data In DTC Ads

This article was originally published in The Pink Sheet Daily

Executive Summary

Study of "format variations" in the brief summary of print advertisements will test different ways of presenting benefit and risk information.

You may also be interested in...



FDA’s Biggest DTC Advertising Study Eyes Online Promotion

The agency has 11 research projects under way, including a $2 million study of online Rx drug promotion; pharma spending on direct-to-consumer advertising declined in 2012 with biggest spends on Cymbalta and Cialis ads.

Can't Please Everybody: FDA's "Brief Summary" Redesign May Require Flexibility

Drug Facts Box format scored well in a broad study, but researchers found it may not be the best format for everyone.

Can't Please Everybody: FDA's "Brief Summary" Redesign May Require Flexibility

Drug Facts Box format scored well in a broad study, but researchers found it may not be the best format for everyone.

Related Content

Topics

UsernamePublicRestriction

Register

PS071117

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel